Pre-Operative PARPi and Irradiation (POPI) in Women with an Incomplete Response to Neo Adjuvant Chemotherapy (NAC) for Breast Cancer.
The purpose of this study is to determine the number of participants who can handle the treatment within specific safety parameters, determine the number of participants who can handle safely the maximum tolerated dose (MTD) (within 50-200 mg/BID dose range) when combining Veliparib and radiation, as well as to identify side effects and their intensity at different dosing levels.
The purpose of this study is to identify the side effects, if any, when radiation and Veliparib are given together to treat women who still have cancer in their breast or under arm lymph nodes after being treated with pre-surgery chemotherapy.
- IRB Number: 1503214668 (J11155)
- Research Study Identifier: TX5475
- Principal Investigator: Richard Zellars, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required